Lexicon Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Michael S. Exton
- Full Time Employees
- 81
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2445 Technology Forest Boulevard The Woodlands TX United States of America 77381
- IPO Date
- Apr 7, 2000
- CIK
- 0001062822
- Website
- lexpharma.com
- Similar Companies
- Business
- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) is a biopharmaceutical company focused on discovering and developing treatments for diabetes, metabolic disorders, and other chronic diseases through its proprietary gene knockout technology. The company offers a pipeline of investigational drug candidates, including sotagliflozin (brand name Inpefa), an SGLT1 and SGLT2 dual inhibitor approved for heart failure and chronic kidney disease in type 2 diabetes patients; LX9211, a central nervous system-penetrant EP2 receptor antagonist in Phase 2 trials for neuroinflammation-related conditions; LX9851, a peripherally restricted EP2 antagonist for peripheral inflammatory diseases; and earlier-stage programs targeting neuropathic pain, obesity, and hypoparathyroidism. Founded in 1994 and headquartered in The Woodlands, Texas, Lexicon operates primarily in the United States with clinical trials conducted globally. Recent developments include positive Phase 3 trial results for Inpefa in expanding indications announced in late 2024, a strategic licensing partnership with Novo Nordisk for LX9211 development in 2025, and a $100 million financing round closed in Q3 2025 to support pipeline advancement and manufacturing scale-up.
Company News
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Falls 5.2% – Here’s What Happened
Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Recommendation of “Hold” from Brokerages
This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data
Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data
Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
Lexicon Pharmaceuticals Edging Closer To 'Go Time' On Multiple Late-Stage Assets
Lexicon Pharmaceuticals Q2 Earnings Call Highlights
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates
Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)
Here's Why You Should Add LXRX Stock to Your Portfolio Now
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?